NCT01871805 · OUTCOME

Percentage of Participants Who Died Due to Any Cause: Phase II

A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) · Source last updated 2018-08-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of participants
Interval / dispersion: Not reported
Time frame: Baseline up to death (any cause) (maximum follow up 284 weeks)

Analysis population: Phase II safety population

Groups in this outcome

Alectinib 600 mg (Fed): Phase II

Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	87

Reported measurements

Source class 1

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	51.7	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
51.7

denoms

counts
group Id
OG000
value
87
units
Participants

groups

description
Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.
id
OG000
title
Alectinib 600 mg (Fed): Phase II

param Type

NUMBER

population Description

Phase II safety population

reporting Status

POSTED

time Frame

Baseline up to death (any cause) (maximum follow up 284 weeks)

title

Percentage of Participants Who Died Due to Any Cause: Phase II

type

SECONDARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice